This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(21) International Application Number: PCT/EP94/01560 (22) International Filing Date: 11 May 1994 (11.05.94) (23) International Filing Date: 11 May 1994 (11.05.94) (24) International Filing Date: 11 May 1994 (11.05.94) (25) International Filing Date: 11 May 1994 (11.05.94) (26) International Filing Date: 11 May 1994 (11.05.94) (27) International Filing Date: 11 May 1994 (11.05.94) (28) International Filing Date: 11 May 1994 (11.05.94) (29) International Filing Date: 11 May 1994 (11.05.94) (20) International Filing Date: 11 May 1994 (11.05.94) (21) International Filing Date: 11 May 1994 (11.05.94) (22) International Filing Date: 11 May 1994 (11.05.94) (23) International Filing Date: 11 May 1994 (11.05.94) (24) International Filing Date: 11 May 1994 (11.05.94) (25) International Filing Date: 11 May 1994 (11.05.94) (26) International Filing Date: 11 May 1994 (11.05.94) (27) International Filing Date: 11 May 1994 (11.05.94) (28) International Filing Date: 11 May 1994 (11.05.94) (29) International Filing Date: 11 May 1994 (11.05.94) (20) International Filing Date: 11 May 1994 (11.05.94) (21) International Filing Date: 11 May 1994 (11.05.94) (22) International Filing Date: 11 May 1994 (11.05.94) (23) International Filing Date: 11 May 1994 (11.05.94) (24) International Filing Date: 11 May 1994 (11.05.94) (25) International Filing Date: 11 May 1994 (11.05.94) (26) International Filing Date: 11 May 1994 (11.05.94) (27) International Filing Date: 11 May 1994 (11.05.94) (28) International Filing Date: 12 May 1994 (11.05.94) (29) International Filing Date: 12 May 1994 (11.05.94) (20) International Filing Date: 12 May 1994 (11.05.94) (21) International Filing Date: 12 May 1994 (11.05.94) (22) International Filing Date: 12 May 1994 (11.05.94) (23) International Filing Date: 12 May 1994 (11.05.94) (24) International Filing Date: 12 May 1994 (11.05.94) (25) International Filing Date: 12 May 1994 (11.05.94) (26) International Filing Date: 12 May 1994 (11.05.94) (27) International Filing Date: 12 May 1994 (11.05.94) (28) Interna	(51) International Patent Classification ⁵ : C12N 15/82, 15/54, 1/21, 5/10, A01H 5/00	A2	 (11) International Publication Number: WO 94/26913 (43) International Publication Date: 24 November 1994 (24.11.94)
(74) Agent: ERNEST GUTMANN - YVES PLASSERAUD S.A.; 3, rue Chauveau-Lagarde, F-75008 Paris (FR).	(22) International Filing Date: 11 May 1994 (23) (30) Priority Data: 93401237.8 13 May 1993 (13.05.93) (71) Applicant (for all designated States except US): GENETIC SYSTEMS, N.V. [BE/BE]; Kolonel Boto, B-1040 Brussels (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): CORNELISSE cus [NL/BE]; Elibogten 38, B-9070 Heusden (BI NAERTS, Arlette [BE/BE]; Buisstraat 5, B-9031 (BE). GOSSELE, Véronique [BE/BE]; J. Platear B-9000 Gent (BE). VAN AARSSEN, Roel [NL/BI naardsesteenweg 35, B-9000 Gent (BE).	PLAN purgstra EN, Ma E). REY Dronge astraat E]; Zwi	(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, FL, PT, RO, RU, SD, SE, SI, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, MI, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.

(57) Abstract

A method to select and identify transformed plant cells by expressing a chimeric gene encoding an aminoglycoside-6'-N-acetyltransferase in the plant cells in the presence of an aminoglycoside antibiotic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MIR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	Œ	Ireland	NZ	New Zealand
BJ	Benin	п	Italy	.PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RÜ	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo	_	of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
a	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	ш	Liechtenstein	SN	Scregal
CN	China	LK	Sri Lanka	TD	Chad
ČS.	Czechoslovakia	LU	Luxembourg	TG	Togo
čz	Czech Republic	LV	Larvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali -	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

1

MARKER GENE

This invention relates to a chimeric selectable marker gene comprising: a plant-expressible promoter, DNA encoding an aminoglycoside-6'-N-acetyltransferase (the "AAC(6')"), and a 3' end formation and polyadenylation region active in plant cells.

This invention further relates to a process for selecting or identifying transformed plant cells by expressing the chimeric marker gene, encoding the AAC(6'), in the plant cells. The chimeric marker gene confers, on the plant cells, resistance to normally lethal or growth-suppressive concentrations of an antibiotic which is efficiently detoxified by the AAC(6') in the cells.

This invention also relates to a plant cell, stably transformed with the chimeric marker gene, encoding the AAC(6'), and to a plant regenerated from this plant cell.

Background of the invention

Plant genetic engineering technology has made significant progress during the last decade. It has become possible to introduce stably foreign genes into plants. This has provided exciting opportunities for modern agriculture.

The use of chimeric selectable marker genes in plant cell transformation has considerably simplified the selection of transformed plant cells. For example, by the expression of such a marker gene, transformed plant cells can be made resistant to antibiotics that are cytotoxic or growth-suppressing to non-transformed cells. A commonly used chimeric marker gene contains the neomycin phosphotransferase-II or nptII coding region (Bevan et al (1983) Nature 304, 184-187; Fraley et al (1983) Proc. Natl. Acad. Sci USA 80, 4803-4807).

The nptII gene confers resistance to kanamycin, neomycin and G-418 antibiotics on plant cells expressing the gene (Reynaerts et al (1987) Plant Mol. Biol. Manual, Gelvin, S.B. & Schilperoort, R.A. (eds), Kluwer, Dordrecht, sect. A9, pp. 1-16).

Chimeric marker genes have typically contained: a plant-expressible promoter (with a 5' untranslated region); DNA (such as the npt II gene) encoding a 3 1 selectable marker; and a end formation polyadenylation region active in plants. Although the versability of the nptII gene has been confirmed in chimeric marker genes in several plant systems over the years, there have been limitations on its use that have development necessitated the of alternative antibiotic-resistance genes for use in such chimeric selectable marker genes (Hayford et al (1988) Plant Physiol. 86, 1216). Furthermore, in many situations, a second complementary antibiotic-resistance gene has been needed for introduction into plants that have already been transformed with an antibiotic-resistance Such alternative antibiotic-resistance genes already exist, but they often require the use of very toxic substrates and/or they do not allow efficient selection in all plant species. Certainly for species that are routinely vegetatively reproducible, potato, antibiotic-resistance genes encoding different selectable markers, with different specific substrates, are required when different genes have to be engineered at different times into a plant.

Among the known antibiotic-resistance genes are those encoding aminoglycoside antibiotic-acetylating enzymes, four types of (AAC) which have characterized (based on the position of the modified amino group of the 2-deoxystreptamine-derived aminoglycosides):AAC(1), AAC(2'), AAC(3) and AAC(6'). See Shaw et al (1989) Antimicrob. Agents & Chemotherapy

33, 2052-2062. High-pressure liquid chromatography (HPLC) analysis has demonstrated the differences among the acetylated products of these four types of enzymes, and aminoglycoside-resistance profiles can be used to identify the presence of each of these types of enzymes in a host strain (Shaw et al (1989) supra).

European patent publication ("EP") 0 289 478 (Rogers et al (1988), Hayford et al (1988) supra, and Carrer et al (1991) Plant Mol. biol. 17, gentamycin selection describe the on of plants transformed with an aminoglycoside-3-Nacetyltransferase-encoding gene (the "aac(3) gene"). The aac(3)-IV gene was found to confer resistance to kanamycin (in Petunia), but the level of resistance was, at most, only sufficient for marginal selection (Hayford et al (1988) supra). These publications also describe supertransformation of tobacco, previously transformed with the nptII gene, with the aac(3) gene selection gentamycin-containing on. EP 0 289 478 also describes the use of gentamycin as a substrate in the transformation of petunia, soybean, oilseed rape and alfalfa transformed with the aac(3) gene. Carrer et al (1991) supra also describes the transformation of tobacco plants with an aac(3)-I gene, only conferring resistance to gentamycin, whereby the gentamycin-resistant plants retain their sensitivity to kanamycin. According to Carrer et al (1991) supra, it may be more advantageous to use a selectable marker gene with a narrow substrate specificity in some cases.

The AAC(6')-encoding genes (the "aac(6') genes") constitute a class of different but related genes acetylating the 5' amino group of several aminoglycoside antibiotics. Several bacterial aac(6') genes have been cloned and sequenced. According to Davis (1986) In Antibiotics in Laboratory Medicine, pp. 474-489, (ed.) Lorian V., Williams & Wilkins,

Baltimore, Maryland and Phillips & Shannon (1984) British Med. Bull. 40, 28-35, AAC(6') acetylates tobramycin, kanamycin, amikacyn, neomycin, gentamycin C_{1A} and C₂, sissomycin and netilmycin, although with varying efficiencies depending on the kind of AAC(6'). Two subtypes of <u>aac(6')</u> genes have been characterized by their aminoglycoside resistance profiles: <u>aac(6')-I</u> genes and <u>aac-(6')-II</u> genes; the former subclass comprises the <u>aac(6')-IV</u> and -4 genes, and the latter subclass comprises the <u>aac(6')-III</u> gene (Shaw et al (1989) <u>supra</u>). However, other classifications of these genes have also been made.

Another acetyltransferase, phosphinotricin acetyltransferase, has also been found to be capable of conferring a selectable phenotype (i.e., a herbicide resistance) to plant cells (De Block et al (1987) EMBO J. 6, 2513-2518).

EP 0 248 207 (Wohlleben et al, 1987) describes a gentamycin-resistance gene that is active in $\underline{\text{Streptomyces}}$ and is obtainable from a strain of $\underline{\text{S.}}$ ghanaensis by total digestion with BglII.

French patent publication 2 601 965 (Courvalin, 1988) describes a bifunctional gene encoding AAC(6') and APH(2'') activities, the cloning and sequencing of this gene, and the use of parts of the gene as a DNA probe for detecting antibiotic-resistance development in bacterial cultures.

Summary of the invention

In accordance with this invention is provided a chimeric selectable marker gene (the "chimeric <u>aac(6')</u> gene"), comprising the following operably linked elements in the same genetic locus: a plant-expressible promoter; a DNA sequence encoding an AAC(6') (the "<u>aac(6')</u> DNA"), particularly an <u>aac(6')</u> DNA with the sequence of SEQ ID No. 1, under the control of the

promoter; and a 3' end formation and polyadenylation region active in plant cells.

Also in accordance with this invention is provided a method for selecting or identifying transformed plant cells by: transforming the cells with the chimeric <u>aac(6')</u> gene; and then contacting the cells with concentrations of an aminoglycoside antibiotic that are lethal or growth-suppressive to non-transformed plant cells.

Further in accordance with the invention is provided a plant cell, stably transformed with the chimeric <u>aac(6')</u> gene, a plant cell culture and plant regenerated from this plant cell, and a plant transformation vector, a plasmid and an <u>Agrobacterium</u> strain containing the chimeric <u>aac(6')</u> gene.

Detailed Description of the Invention

The term "aac(6') DNA" as used herein means a DNA coding sequence encoding a protein (an "AAC(6')") which catalyses the acetylation of the 6' amino group of aminoglycoside antibiotics. This term includes a partly or fully synthetic DNA sequence, as well as a naturally occurring DNA sequence encoding an AAC(6'). Preferred aac(6') DNAs according to this invention include the DNA of SEQ ID No. 1 and substantially similar DNAs, such as the aac(6') DNAs described by Nobuta et al (1988) J. Bacteriol. <u>170</u>, 3769), Tolmaski (1990) Plasmid 24, 218-226 and Tran van Nhieu and Collatz (1987) J. Bacteriol. 169, 5708. Other aac (6') DNAs of this invention include those described by Davies and Smith (1978) Ann. Rev. Microbiol. 469-518, Morohoshi et al (1984) J. Antibiotics 37, 1687-1691, Tenover et al. (date) J. Bacteriol. 170, 471, Ferretti et al (1986) J. Bacteriol. <u>167</u>, 631, and Shaw et al (1989) Antimicrob. Agents and Chemotherapy 33, 2052.

The term "chimeric <u>aac(6')</u> gene" as used herein means a chimeric selectable marker gene comprising the <u>aac(6')</u> DNA, operably linked to a plant-expressible promoter (including a 5' untranslated region) and a 3' end formation and polyadenylation region active in plants. The <u>aac(6')</u> DNA can also be expressed as a fusion protein in a chimeric gene fusion with another transforming DNA, so as to enhance selection for the desired genotype. The construction of this chimeric gene fusion can be carried out according to techniques derived from methods currently used for constructing chimeric genes comprising known markers.

The term "selectable marker gene" as used herein means a DNA sequence, the expression of which in a plant cell confers a selectable phenotype (e.g., antibiotic resistance) to the plant cell.

The term "translationally neutral modifications" as used herein means modifications of a gene or DNA sequence that do not affect the amino acid sequence encoded by the gene or DNA sequence. Preferred examples of such translationally neutral modifications are changes, by means of nucleotide substitutions, of codons into other codons encoding the same amino acids.

The term "suitable substrate" or "suitable substrate antibiotic" as used herein is an aminoglycoside antibiotic (e.g., kanamycin) which is efficiently modified by AAC(6') so that expression of the <u>aac(6')</u> DNA in a plant cell confers resistance on the plant cell to the antibiotic. Hence, the term "substrate of an AAC(6')" as used herein means any aminoglycoside antibiotic which can be modified, i.e. acetylated, by the <u>aac(6')</u> gene product.

An <u>aac(6')</u> DNA of this invention can easily be isolated from bacteria by routine procedures after cultivation on a suitable substrate containing normally inhibitory levels of an aminoglycoside antibiotic, such

as kanamycin, for example as described by Nobuta et al (1988) J. Bacteriol. 170, 3769. AAC(6') activity can be assayed by conventional methods (Davies (1986) supra; Shaw et al (1989) supra).

Preferably, an aac(6") DNA of this invention is inserted in a plant genome downstream (i.e., 3') of, and under the control of, a promoter which can direct the expression of the gene in plant cells. Preferred promoters include, but are not limited to, the strong constitutive 35S promoter (Odell et al (1985) Nature 313, 810) or duplicated 35S promoter (Kay et al (1987) Science 236, 1299) of cauliflower mosaic virus; 35S promoters have been obtained from different isolates (Hull & Howell (1987) Virology 86, 482-493). Other preferred promoters include the TR1' promoter and the TR2' promoter (Velten et al (1984) EMBO J. 3, 2723). Also preferred are monocot promoters such as promoters described in EPO 0 342 926 or EP 0 459 643. Alternatively, a promoter can be utilized which is not constitutive but rather is specific for one or more plant tissues or organs. For example, the aac(6') DNA can be selectively expressed in the green tissues of a plant by placing the DNA under the control of a lightinducible promoter such as the promoter ribulose-1,5-bisphosphate-carboxylase small subunit gene as described in EP 0 193 259. Another alternative is to use a promoter whose expression is inducible by temperature or chemical factors or a promoter that is expressed preferentially or selectively in the time period or the developmental stage at which cells are selected, such as a callus-specific promoter, which have been used previously with other markers. In any event, it is evident that a promoter for use in this invention must at least allow sufficient expression of the <u>aac(6')</u> DNA in plant cells to confer antibioticresistance to the plant cells.

Ιt preferred that the aac(6') 5') of inserted upstream (i.e., suitable 3 1 transcription regulation signals (i.e., transcript 3' end formation and polyadenylation signals). Preferred 3' transcription regulation signals include those of the chalcone synthase gene (Sommer & Saedler (1986) Mol. Gen. Genet. 202, 429), the cauliflower mosaic virus (Mogen et al (1990) The Plant Cell 2, 1261), the octopine synthase gene (Gielen et al (1984) EMBO J. 3, 835) or the T-DNA gene 7 (Velten & Schell (1985) Nucl. Acids Res. 13, 6981).

In accordance with this invention, all or part of an aac(6') DNA of this invention can be stably inserted in a conventional manner into the nuclear genome of a plant cell, and the so-transformed plant cell can be used to produce a transgenic plant showing resistance to aminoglycoside antibiotics. regard, a disarmed Ti-plasmid containing the chimeric aac(6') gene in Agrobacterium (e.g., A. tumefaciens) can be used to transform a plant cell using the procedures described, for example, in EP 0 116 718 and 270 822, PCT publication WO 84/02913, 242 246, De Block (1988) Theor. Appl. Genet. 767-774, and Gould et al (1991) Plant Physiol. 95, 426 (which are incorporated herein by reference). Preferred Ti-plasmid vectors contain the chimeric aac(6') gene between the border sequences; or at least located to the left of the right border sequence, of the T-DNA of the Ti-plasmid. Of course, other types of vectors can be used to transform the plant cell, using procedures such as direct gene transfer (as described, EP 0 233 247), example, in pollen transformation (as described, for example, in EP 0 270 356, PCT publication WO 85/01856, and patent 4,684,611, plant RNA virus-mediated transformation (as described, for example, in

patent 4,407,956), liposome-US EP 0 067 553 and mediated transformation (as described, for example, in US patent 4,536,475) and other methods such as the methods for transforming monocots (e.g., the major cereals including corn, rice, wheat, barley and rye) as described in PCT publication WO 92/09696. In case the plant to be transformed is corn, other developed methods can also be used such as, example, the method described for certain lines of corn by Fromm et al (1990) Bio/Tech. 8, 833, Gordon-Kamm et al (1990) The Plant Cell 2, 603, and Gould et al (1991) supra. In case the plant to be transformed is rice, other recently developed methods can also be used such as, for example, the methods described by Shimamoto et Nature 338, 274), Datta et (1989) Bio/tech. 8, 736 and Hayashimoto et al (1990) Plant Physiol. 93, 857.

In order to improve the expression of the chimeric aac(6") gene of this invention in a plant, the aac(6') DNA can be modified, for example by changing codon usage to form an equivalent natural artificial aac(6') DNA. Such modifications can include introducing functional introns and/or translationally neutral modifications into the aac(6") DNA sequence in order to eliminate deleterious DNA sequences present in this bacterial DNA, such as are described in PCT patent application PCT/EP92/02547. This can be done directly by modifying (in a translationally neutral manner) such deleterious DNA sequences, inhibiting expression in the plant cells, or indirectly by adapting the codon usage of the aac(6') DNA to that preferred by the plant, for example as described by Murray et al (1989) Nucleic Additionally for achieving Res. 17, 477. sufficient expression in monocot plants such as corn, an efficiently spliced monocot intron, e.g. intron 1 from the corn adh gene, can be added to the chimeric <u>aac(6')</u> gene (Koziel et al (1993) Bio/Tech. <u>11</u>, 194-200).

transformed plant of this regenerated from a plant cell transformed with the aac(6') gene, shows resistance against chimeric substrate antibiotics by virtue of suitable production of AAC(6') activity in its plant cells. Such a plant can be used in a conventional breeding scheme to produce more transformed plants with the same aminoglycoside antibiotic-resistance characteristics or to introduce the chimeric <u>aac(61)</u> gene into other varieties of the same or related plant species by standard breeding techniques. Seeds, which are obtained from the transformed plants, contain the chimeric aac(6') gene as a stable genomic insert.

Since the spectrum of antibiotics which can be chemically modified by expression of an aac(6') DNA of this invention is different from that of the nptII coding region, the aac(6') DNA can be used with the nptII coding region in different chimeric selectable marker genes where two different foreign genes are to be introduced into a plant, with each foreign gene being associated with its own chimeric marker gene. When engineering multiple chimeric marker genes in a plant, it may be advantageous to use a chimeric aac(6') gene only conferring resistance to a limited group of aminoglycoside antibiotics (Carrer et al (1991) supra). However, if only one chimeric marker gene is to be used, it is preferred to use a chimeric aac(6') gene with kanamycin as the suitable substrate for plant cells. In this regard, the enzymatic assay detecting acetyltransferase activity is often quicker and more convenient to use than the phosphotransferase assay used to detect nptII-activity.

To test for the successful transformation of plants with an $\underline{aac}(6')$ DNA, different methods are

available. For example, antibiotic-resistance can be checked in a callus induction test or a dot application assay; the presence and the activity of AAC (6') can also be analyzed by an enzymatic assay; Western blotting can provide an easy immunological test but is less sensitive; and kanamycin resistance can be followed in the progeny of transgenic plants by the sowing of seeds on kanamycin-containing media.

The following Examples illustrate the invention. Unless otherwise stated in the Examples, all procedures for making and manipulating recombinant DNA are carried out by the standardized procedures described in Sambrook et al, Molecular Cloning - A laboratory Manual, Second Ed., Cold Spring Harbor Laboratory Press, NY (1989) or in Ausubel et al., Current Protocols in Molecular Biology, vols. 1 and 2, Current Protocols, USA (1994).

Sequence Listing

SEQ ID No. 1 shows: i) the DNA sequence of an aac(6')
DNA which comes from a Shigella
plasmid, and ii) the corresponding amino acid sequence encoded by the aac(6') DNA.

SEQ ID No. 2 shows: the amino acid sequence of the AAC(6') protein.

SEQ ID No. 3 shows: the nucleotide sequence of PCR primer "RVA61".

SEQ ID No. 4 shows: the nucleotide sequence of PCR primer "OFD15".

SEQ ID No. 5 shows: the plasmid "pTRVA3" containing a chimeric <u>aac(6')</u> gene with a 35S-2 promoter, the <u>aac(6')</u> DNA of SEQ ID No. 1, and the 3' end formation

12

and polyadenylation region from T-DNA gene 7.

SEG ID No. 6 shows: the amino acid sequence of the AAC(6') protein.

Examples

Example 1. Cloning of an <u>aac(6')</u> DNA and construction of a chimeric aac(6') gene

The aac(6') DNA was obtained from the mini-Sa plasmid, pGV1106 (Leemans et al (1982) Gene 19, 361-364). The 1.5 Kb PvuII/HindIII fragment of pGV1106, containing the aac(6') DNA, was ligated to the ScaIlinearized plasmid pGSC1600 (Cornelissen & Vandewiele (1989) Nucl. Acids Res. 17, 19-29) after Klenow treatment. The resultant plasmid, pFD1002A, was used as a template for PCR, using the primers RVA61 and OFD15, of SEQ ID Nos. 3 and 4, respectively. RVA61 is complementary to the non-coding strand of the aac(6') DNA and its untranslated sequences in pFD1002A. The Sall/BamHI <u>aac(6')</u> PCR fragment of pFGD1002A ligated to the 7.2 Kb Sall/BamHI fragment of the plasmid pGSJ290, containing the chimeric P35S-nptII-3'g7, to yield the plasmid, PTRVA3, of SEQ ID No. 5.

pGSJ290 was derived from pGV825 (Deblaere et al (1985) Nucl. Acids Res. 13, 4777-4787), in which a chimeric P35S-nptII-3'g7 gene construct was cloned between T-DNA border repeats. The 3' untranslated end of the T-DNA gene 7 (i.e., 3'g7) was as described by Velten & Schell (1985) aac(6')supra, the nptII gene was from pKM109/90 (Reiss et al (1984) EMBO J. 3, 3317-3322), and the CaMV 35S promoter (i.e., P35S) was a cauliflower mosaic virus 35S-2 promoter as described in EP 0 193 259 and in Gardner et al (1981) Nucl. Acids

Res. 9, 2871-2888. The chimeric p35S-nptII-3'g7 gene construct was cloned between the HpaI and BglII sites of the T-DNA between the right and left border repeats of pGV825.

Due to the introduction of a <u>Bam</u>HI restriction site downstream of its translation initiation site, the <u>aac(6')</u> DNA sequence in pTRVA3, as shown in SEQ ID No. 5, contained the amino acids Asp and Pro at amino acid positions 2 and 3, respectively, and contained the chimeric <u>aac(6')</u> gene, P35S-<u>aac(6')</u> -3'g7, including the aac(6') DNA with the sequence of SEQ ID No. 1.

Example 2. Selection of $\underline{aac}(6')$ -transformed tobacco cells on kanamycin.

Plasmids pTRVA3 and pGSJ290 were mobilized from E. coli into A. tumefaciens strain C58C1-Rif^R (pGV2260; Deblaere et al (1985) supra) by means of a triparental cross as described by Deblaere et al (1985) supra and EP 0 193 259. The resultant Agrobacteria were selected on minimal A medium (Miller (1972) Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Tobacco cv Petit Havana SR1 cells were cocultivated with these Agrobacteria, and transformed tobacco cells were selected using antibiotic resistance according to De Block et al (1984) EMBO J. 3, 1681-1689. Agrobacterium strains used for infection of tobacco protoplasts were: C58C1-RifR (pGV2260) as a negative control, C58C1-RifR (pGV2260::pTRVA3) which contains the aac(6') DNA, and C58C1-Rif^R (pGV2260::pGSJ290) which contains the nptII gene. One week after infection, the protoplasts were transferred to selective media containing one of the following different concentrations of kanamycin. sulphate (Km):0-25-50-100,6200 μ g/ml.

Seven weeks after infection, calli started growing from cells cocultivated with C58C1-Rif $^{\rm R}$

(pGV2260::pTRVA3) and C58C1-Rif^R (pGV2260::pGSJ290) at all Km concentrations. Protoplasts infected with pGV2260 (negative control) only formed calli on medium without Km. After transfer of the calli to shoot-inducing medium containing 200 μ g/ml Km, shoots were readily formed. Southern analysis of DNA extracted from kanamycin-resistant regenerated tobacco plants confirmed the stable integration of the <u>aac(6')</u> DNA.

Example 3. Selection of $\underline{aac}(6')$ -transformed potato cells on kanamycin.

discs of potato variety Yesmina were cocultivated with Agrobacterium tumefaciens strains C58C1-RifR (pGV2260::pTRVA3) and C58C1-RifR (pGV2260::pGSJ290), carrying the chimeric genes of Example 2 containing either the aac(6') DNA or nptII gene as described by De Block (1988) supra. The leaf discs were transferred to callus induction medium containing 50 μ g/ml kanamycin sulphate. About 30% of the leaf discs that cocultivated were Agrobacterium C58C1-Rif^R (pGV2260::pGSJ290) growing calli in the presence of kanamycin, while about 70% of the leaf discs that were cocultivated with Agrobacterium C58C1-RifR (pGV2260::pTRVA3) growing calli after culturing for 6 weeks on kanamycin medium. After transfer of the aac(6") -transformed calli to shoot-regenerating medium, shoots readily The regenerated potato plants are found to retain the kanamycin-resistant phenotype. analysis of DNA extracted from the kanamycin-resistant potato plants and their progeny confirms the integration of the aac(6') DNA.

Example 4. Assay for enzymatic activity in <u>aac(6')-</u> transformed plants.

The tobacco callus and leaf tissue of Example 2 containing the chimeric aac(6') gene, showed AAC(6') activity when tested in a Thin Layer Chromatography (TLC)-acetyltransferase assay for kanamycin. for acetyltransferase assay determining phosphinotricin-acetyltransferase activity according to De Block et al (1987) EMBO J. 6, 2513-2518 was used, with the exception that kanamycin sulphate was used as substrate instead of phosphinotricin concentration which was twice the concentration of phosphinotricin used by De Block et al (cf. supra), and 2 µl of 14C-acetylcoenzyme A were added instead of a mixture containing both the radioactive and the nonradioactive form of the enzyme. Upon incubation for 30 minutes at 37°C, the reaction mixture was spotted onto TLC plates, and the reaction products were separated by chromatography in 1-propanol/NH₄OH (3/2). Extracts of calli containing the chimeric aac(6') catalyzed the acetylation of kanamycin, while no reaction was observed with extracts of calli from nontransformed SR1 plants and from nptII-expressing calli. Also extracts from leaf tissue of regenerated aac(6') -transformed tobacco plants were found to efficiently acetylate kanamycin.

Needless to say, this invention is not limited to tobacco or potato plants transformed with the aac(6') DNA. It includes any plant, such as tomato, cotton, rapeseed, alfalfa, sunflower, corn, rice, soybean, brassica, sugar beet and other vegetables, transformed with an aac(6') DNA.

Nor is this invention limited to the use of the chimeric $\underline{aac}(6')$ gene of SEQ ID No. 5 or the $\underline{aac}(6')$ DNA of SEQ ID No. 1 for transforming plant cells so

that they express an AAC(6'). Other natural and artificial chimeric genes and DNA can be used. In this regard, the <u>aac(6')</u> DNA sequences of SEQ ID Nos. 1 and 5 can be modified by: 1) replacing some codons with others that code either for the same or different, preferably the same, amino acids; and/or 2) deleting or adding some codons; provided that such modifications do not substantially alter the properties, especially the capacity to detoxifly aminoglycoside antibiotics, of the encoded AAC(6').

All publications referred to in this application are hereby incorporated by reference.

CLAIMS

- 1. A chimeric selectable marker gene for transforming a plant to render it resistant to an aminoglycoside antibiotic (e.g., kanamycin); said marker gene comprising in sequence:
 - a) a plant-expressible promoter;
 - b) an aac(6') DNA; and
- c) a 3' end formation and polyadenylation region active in plant cells.
- 2. The marker gene of claim 1, wherein the <a href="mailto:aac(6') DNA: a) encodes the AAC(6') of SEQ ID No. 1 or b) has either i) the DNA sequence of SEQ ID No. 1 or ii) a variant thereof encoding an AAC(6') with substantially the same antibiotic-detoxifying properties as the AAC(6') of SEQ ID No. 1.
- 3. A method for selecting or identifying transformed plant cells, comprising the steps of: transforming plant cells with a foreign DNA comprising the marker gene of claim 1 or 2; and then growing said transformed cells in concentrations of an aminoglycoside antibiotic, such as kanamycin, that are lethal or growth-suppressive to non-transformed plant cells.
- 4. A plant cell, the nuclear genome of which contains the marker gene of claim 1 or 2.
- 5. A plant, seed or plant cell culture comprising a plurality of the plant cells of claim 4.
- 6. A plant genome containing the marker gene of claim 1 or 2.
- 7. A plant transformation vector, particularly a Ti plasmid, containing the marker gene of claim 1 or 2.
- 8. <u>Agrobacterium tumefaciens</u> containing the vector of claim 7.

- 9. A method for rendering a plant cell resistant to an aminoglycoside antibiotic (e.g., kanamycin); the method comprising the step of: transforming the nuclear genome of the cell with the marker gene of claim 1 or 2.
- 10. A method for detoxifying an aminoglycoside antibiotic in a plant cell; the method comprising the step of: providing the marker gene of claim 1 or 2 in the nuclear genome of the cell.